News at a glance

Galenica posts strong sales growth in a challenging market environment

Galenica achieves sales growth of 7.3% to CHF 1,409.7 million in the first four months of 2026. The main driver is strong growth in the pharmacy business and wholesale.

Galenica achieves strong annual result and increases mid-term guidance

Galenica increases sales in 2025 by 5.5% to CHF 4,135.6 million – all business areas contribute to growth.Adjusted¹ EBIT increases by 11.3% to CHF 234.8 million.

Galenica focuses Bichsel’s business on home care services

Bichsel intends to discontinue pharmaceutical production by the end of 2026 at the latest for economic reasons. This affects up to 170 jobs.

Galenica continues to grow: sales increase to over CHF 4 billion

Sales up by 5.5% to CHF 4,135.

Galenica remains on growth track

Galenica Group sales grew 4.7% to CHF 2,999.7 million in the third quarter of 2025.Sales growth is driven by prescription drugs and dietary supplements.

Galenica demonstrates pleasing growth and improves EBIT guidance

Galenica Group sales grew by 5.0% to CHF 1,995.4 million in the first half of 2025.Adjusted EBIT¹ increased by 10.9% to CHF 109.

Galenica to enter the diagnostics business by acquiring Labor Team

By acquiring the Labor Team Group, Galenica is adding a leading Swiss diagnostic service provider to its healthcare network.

Galenica continues sales growth

Sales growth of 4.7% to CHF 1,314.2 million Strong growth in all key business areas Guidance for 2025 confirmed – sales growth of 3-5% and EBIT¹ growth of 4-6% expected

Galenica continues to grow in 2024

With sales up 4.7% in the 2024 financial year, the Galenica Group grew strongly and generated consolidated net sales of CHF 3,921.1 million.

Galenica reports strong sales growth once again

Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million.

Galenica increases sales growth in the third quarter

Following solid sales growth of 2.6% in the first half of 2024, Galenica grew more strongly again in the third quarter and generated net sales of CHF 2,864.

Galenica achieves solid growth in a challenging market environment

Galenica Group sales grew by 2.6% to CHF 1,900.0 million in the first half of 2024.

Galenica on track with sales growth

The Galenica Group made a good start to the new year with sales growth of 4.8% to CHF 1,255.5 million in the first four months of 2024.

Galenica continues to grow in the 2023 financial year

The Galenica Group achieved strong growth with an increase in sales of 4.4% in the 2023 financial year and generated consolidated net sales of CHF 3,746.0 million.

Galenica again achieves strong sales growth

Galenica Group sales performed well in 2023, growing by 4.4% to CHF 3,746.0 million. As expected, sales growth of 3.

Galenica Investor Day: Updated mid-term guidance and strategy update

Galenica achieves strong sales growth in the first half of 2023

Galenica lowers EBIT guidance 2023 due to special factors – Sales and dividend outlook confirmed

Green light for Switzerland’s leading online pharmacy

Galenica and Shop Apotheke Europe enter into a strategic partnership and establish the leading online pharmacy in Switzerland

Galenica achieves strong results in 2022 and increases dividend again

Change to the Board of Directors of the Galenica Group

2022 Galenica Group sales

Galenica Group half-year results 2022